Cargando…
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
Effective drugs are needed for lung cancer, as this disease remains the leading cause of cancer-related deaths. Rexinoids are promising drug candidates for cancer therapy because of their ability to modulate genes involved in inflammation, cell proliferation or differentiation, and apoptosis through...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746742/ https://www.ncbi.nlm.nih.gov/pubmed/33335263 http://dx.doi.org/10.1038/s41598-020-79260-8 |